U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
COB9FF6I46
US Approved Rx (2017)
First approved in 2017
General
Record Details
Names
6
Identifiers
3
Concept Definition
Relationships
1
Active Moiety
1
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
COB9FF6I46
US Approved Rx (2017)
First approved in 2017
General
Approval Year
2017
422
Record Details
Substance Class
Concept
Record UNII
COB9FF6I46
Record Status
Validated (UNII)
Record Version
10
9
8
7
6
5
4
3
2
1
Names
6
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
Common Name
English
RECOMBINANT VARICELLA ZOSTER VIRUS (VZV) GLYCOPROTEIN E
Preferred Name
English
SHINGRIX
Brand Name
English
HERPES ZOSTER VACCINE GSK1437173A
Common Name
English
GSK-1437173A
Common Name
English
Showing 1 to 5 of 6 entries
Previous
1
2
Next
Identifiers
3
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
NCI_THESAURUS
C88288
PRIMARY
DAILYMED
COB9FF6I46
PRIMARY
FDA UNII
COB9FF6I46
PRIMARY
Showing 1 to 3 of 3 entries
Previous
1
Next
Concept Definition
This is a non-substance concept
Relationships
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
9885M7D6JP
HUMAN HERPESVIRUS 3
TARGET ORGANISM->VACCINE ANTIGEN
Showing 1 to 1 of 1 entries
Previous
1
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
COB9FF6I46
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
This is a non-substance concept
